The Daily Biotech Pulse: Merck’s Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand
Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.
‘Unused taxpayer-backed vaccine factory to be sold to US bidder’ -The Telegraph Report
https://www.telegraph.co.uk/business/2022/02/18/unused-taxpayer-backed-vaccine-factory-sold-us-bidder/
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson’s Program
Here's a roundup of top developments in the biotech space over the last 24 hours:
Catalent’s Q2 Earnings Beat Street View, Lifts FY22 Guidance
Catalent Inc (NYSE: CTLT) has reported Q2 FY22 sales of $1.
A Bearish Sign Appears On Catalent’s Chart
If history is any guide, there may be trouble ahead for shares of Catalent (NYSE:CTLT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Expert Ratings For Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter:
Barclays Maintains Overweight on Catalent, Lowers Price Target to $130
Barclays analyst Luke Sergott maintains Catalent (NYSE:CTLT) with a Overweight and lowers the price target from $160 to $130.
FDA Concerns At Catalent Site Spurred Novo Nordisk’s Wegovy Supply Woes: Report
Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) o